Hironori Ochi
Matsuyama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 213 publications
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 29, 2026
Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
Journal: Anticancer research
Published: May 14, 2026
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
Journal: Oncology
Published: April 19, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 07, 2026
Response to 'Letter to the Editor: "Effect of Direct-Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan".
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: March 29, 2026
Response to 'Comment on "Effect of Direct-Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan"'.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: February 28, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.
Journal: Hepatology (Baltimore, Md.)
Published: January 27, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
Journal: Journal of gastroenterology and hepatology
Published: January 19, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 13, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 12, 2026
Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings.
Journal: Internal medicine (Tokyo, Japan)
Published: January 04, 2026
Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: December 12, 2025
Last Updated: 09/26/2026